Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Olnes

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Hematological Oncology|April 30, 2014
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapyLewis R Silverman, Peter Greenberg, Azra Raza, et al.
Scientific Reports|March 15, 2016
Effects of Systemically Administered Hydrocortisone on the Human ImmunomeMatthew J Olnes, Yuri Kotliarov, Angélique Biancotto, et al.
Plos One|December 19, 2013
Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjectsAngelique Biancotto, Abigail Wank, Shira Perl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2010
Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissionsElaine M Sloand, Matthew J Olnes, Aarthie Shenoy, et al.
Transfusion|September 3, 2011
Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donorsMatthew J Olnes, Andrea Poon, Susan J Miranda, et al.
Blood|December 19, 2013
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drugRonan Desmond, Danielle M Townsley, Bogdan Dumitriu, et al.
Genes & Cancer|August 19, 2010
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive InhibitionShashidhar S Jatiani, Stephen C Cosenza, M V Ramana Reddy, et al.
Cell|April 15, 2014
Global analyses of human immune variation reveal baseline predictors of postvaccination responsesJohn S Tsang, Pamela L Schwartzberg, Yuri Kotliarov, et al.
The New England Journal of Medicine|July 6, 2012
Eltrombopag and improved hematopoiesis in refractory aplastic anemiaMatthew J Olnes, Phillip Scheinberg, Katherine R Calvo, et al.
Leukemia Research|April 25, 2012
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.NaMatthew J Olnes, Aarthie Shenoy, Barbara Weinstein, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Hematological Oncology|April 30, 2014
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapyLewis R Silverman, Peter Greenberg, Azra Raza, et al.
Scientific Reports|March 15, 2016
Effects of Systemically Administered Hydrocortisone on the Human ImmunomeMatthew J Olnes, Yuri Kotliarov, Angélique Biancotto, et al.
Plos One|December 19, 2013
Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjectsAngelique Biancotto, Abigail Wank, Shira Perl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2010
Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissionsElaine M Sloand, Matthew J Olnes, Aarthie Shenoy, et al.
Transfusion|September 3, 2011
Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donorsMatthew J Olnes, Andrea Poon, Susan J Miranda, et al.
Blood|December 19, 2013
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drugRonan Desmond, Danielle M Townsley, Bogdan Dumitriu, et al.
Genes & Cancer|August 19, 2010
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive InhibitionShashidhar S Jatiani, Stephen C Cosenza, M V Ramana Reddy, et al.
Cell|April 15, 2014
Global analyses of human immune variation reveal baseline predictors of postvaccination responsesJohn S Tsang, Pamela L Schwartzberg, Yuri Kotliarov, et al.
The New England Journal of Medicine|July 6, 2012
Eltrombopag and improved hematopoiesis in refractory aplastic anemiaMatthew J Olnes, Phillip Scheinberg, Katherine R Calvo, et al.
Leukemia Research|April 25, 2012
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.NaMatthew J Olnes, Aarthie Shenoy, Barbara Weinstein, et al.
Pageof 3